H&M (HMB SS): Most Crowded in Sweden

Author:

S3 Research Team

August 21, 2025

Short Interest 21% of Float, Squeeze and Crowded Score 87.5, Analyst Downgrades

Hennes & Mauritz, better known as H&M, is a Swedish multinational retailer specializing in apparel and department store offerings, trading under the ticker HMB SS.

HMB is a $25 billion USD market-cap company and ranks among the largest constituents of the OMX Stockholm 30 Index, highlighting its significance in European equity markets.

H&M’s Short Squeeze Score and Crowded Shorts data both register at 87.5, reflecting high short-selling sentiment and increased short squeeze risk.

The Short Interest % of Float stands at a notable 21.17%, further underscoring the potential for a short squeeze event, up from 18% at the beginning of the year.

The stock is currently down 3% year-to-date (YTD), underperforming major retail benchmarks and reflecting bearish sentiment among market participants.

My image alt text
My image alt text

Sell-side sentiment has deteriorated sharply: 43% of analyst ratings are now “sell”, up from 25%, while buy ratings have fallen to just 15%, down from 55%—a dramatic shift in market perception.

Notably, none of the recent analyst recommendations are “buys”, underscoring the intensifying skepticism from institutional investors and hedge funds.

My image alt text

Want to know more? Access this data in real time using S3’s BLACK APP & BLACK MAP


The information herein (some of which has been obtained from third party sources without verification) is believed by S3 Partners, LLC (“S3 Partners”) to be reliable and accurate. Neither S3 Partners nor any of its affiliates makes any representation as to the accuracy or completeness of the information herein or accepts liability arising from its use. Prior to making any decisions based on the information herein, you should determine, without reliance upon S3 Partners, the economic risks, and merits, as well as the legal, tax, accounting, and investment consequences, of such decisions.

Related Articles

Oracle (ORCL): Cap and Short Interest Up

August 20, 2025

New Novo Shorts Ahead of FDA Approval

August 19, 2025

Crowded Hedge, Key Resistance: XBI

August 20, 2025